Literature DB >> 27601364

Pelvic Lymph Node Staging by Combined 18F-FDG-PET/CT Imaging in Bladder Cancer Prior to Radical Cystectomy.

Renate Pichler1, Tobias De Zordo2, Josef Fritz3, Alexander Kroiss4, Friedrich Aigner2, Isabel Heidegger5, Irene Virgolini4, Wolfgang Horninger5, Christian Uprimny4.   

Abstract

BACKGROUND: Accurate lymph node (LN) staging in bladder cancer before radical cystectomy is essential as LN metastases have an independent prognostic value. Most studies used a cutoff of > 10 mm in detecting pelvic LN spread. The aim of this study was to evaluate the diagnostic accuracy of contrast-enhanced computed tomography (CT) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) alone, or combined for preoperative pelvic LN staging. PATIENTS AND METHODS: We retrospectively analyzed the data of 70 bladder cancer patients that were staged with 18F-FDG-PET/CT before radical cystectomy between 2012 and 2015. 18F-FDG-PET images were analyzed visually and semi-quantitatively by calculating the maximum standardized uptake value. CT scans were reviewed using different cutoffs of pelvic LNs, with the best cutoff at 8 mm (area under the curve = 0.684).
RESULTS: Metastatic LNs were confirmed in 53 (2.8%) of 1906 resected LNs in 11 (15.7%) patients. Sensitivity, specificity, and accuracy were 54.5%, 89.8%, and 84.3% for 18F-FDG-PET alone; 45.5%, 91.5%, and 84.3% for CT (LNs > 8 mm) alone; and 27.3%, 96.6%, and 85.7% for CT (LNs > 10 mm) alone, respectively. Combined 18F-FDG-PET/CT resulted in a nonsignificant increase of diagnostic accuracy using a cutoff > 8 mm for LN evaluation (63.6%, 86.4%, and 82.9%, respectively). A significant improvement of sensitivity to 63.6% was achieved only when LNs > 10 mm were considered suspicious (P = .046), but this reduced specificity to 88.1% (P = .025).
CONCLUSIONS: Combined 18F-FDG-PET/CT does not seem to be justified in preoperative staging if the threshold of pelvic LNs is set > 8 mm.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CT; Cystectomy; Lymph node metastases; PET; Preoperative staging

Mesh:

Substances:

Year:  2016        PMID: 27601364     DOI: 10.1016/j.clgc.2016.08.009

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  12 in total

Review 1.  Advances in Imaging in Prostate and Bladder Cancer.

Authors:  Abhishek Srivastava; Laura M Douglass; Victoria Chernyak; Kara L Watts
Journal:  Curr Urol Rep       Date:  2017-09       Impact factor: 3.092

2.  Increasing use of positron emission tomography among medicare beneficiaries undergoing radical cystectomy.

Authors:  Avinash Maganty; Robert M Turner; Jonathan G Yabes; Dwight E Heron; Jeffrey R Gingrich; Benjamin J Davies; Bruce L Jacobs
Journal:  Eur J Cancer Care (Engl)       Date:  2020-02-05       Impact factor: 2.520

3.  Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma.

Authors:  Scott P Campbell; Alexander S Baras; Mark W Ball; Max Kates; Noah M Hahn; Trinity J Bivalacqua; Michael H Johnson; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Ann Nucl Med       Date:  2017-10-24       Impact factor: 2.668

4.  Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer.

Authors:  Antoine Girard; Mathieu Rouanne; Sarah Taconet; Camélia Radulescu; Yann Neuzillet; Astrid Girma; Aurélie Beaufrere; Thierry Lebret; Elise Le Stanc; Jean-François Grellier
Journal:  Eur Radiol       Date:  2019-01-21       Impact factor: 5.315

Review 5.  Evaluation of lymph node status in patients with urothelial carcinoma-still in search of the perfect imaging modality: a systematic review.

Authors:  Michał Frączek; Hubert Kamecki; Anna Kamecka; Roman Sosnowski; Katarzyna Sklinda; Marcin Czarniecki; Leszek Królicki; Jerzy Walecki
Journal:  Transl Androl Urol       Date:  2018-10

Review 6.  The Role of Imaging in Bladder Cancer Diagnosis and Staging.

Authors:  Samuel J Galgano; Kristin K Porter; Constantine Burgan; Soroush Rais-Bahrami
Journal:  Diagnostics (Basel)       Date:  2020-09-16

Review 7.  Role of PET/CT in muscle-invasive bladder cancer.

Authors:  Seok-Ki Kim
Journal:  Transl Androl Urol       Date:  2020-12

8.  The management of muscle-invasive bladder Cancer is still a significant challenge in the clinical practice.

Authors:  Arie Carneiro
Journal:  Int Braz J Urol       Date:  2022 Jan-Feb       Impact factor: 1.541

Review 9.  The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.

Authors:  Vincenzo Cuccurullo; Giuseppe Danilo Di Stasio; Francesco Manti; Pierpaolo Arcuri; Rocco Damiano; Giuseppe Lucio Cascini
Journal:  Diagnostics (Basel)       Date:  2021-05-11

Review 10.  Imaging of Bladder Cancer: Standard Applications and Future Trends.

Authors:  Rasha Taha Abouelkheir; Abdalla Abdelhamid; Mohamed Abou El-Ghar; Tarek El-Diasty
Journal:  Medicina (Kaunas)       Date:  2021-03-01       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.